All News
Filter News
Found 86 articles
-
Adagio Therapeutics Announces $336 Million Series C Financing to Support Rapid Advancement of Novel ADG20 Antibody for the Treatment and Prevention of COVID-19
4/19/2021
Adagio Therapeutics, Inc., a biotechnology company developing best-in-class antibodies to broadly neutralize coronaviruses, announced the completion of a $336 million Series C financing led by RA Capital Management, with participation from new investors, including Redmile Group, Federated Hermes, Foresite Capital, ArrowMark Partners, PremjiInvest, and another leading healthcare investor.
-
Adagio Therapeutics Initiates Global Clinical Trial of ADG20 as a Treatment for COVID-19
4/13/2021
Phase 1/2/3 STAMP Trial to be Conducted Globally, Including in Countries with High Rates of SARS-CoV-2 Variants Resistant to Other Monoclonal Antibody Products
-
Neptune Wellness Solutions Inc. President Michael Cammarata Named Top 25 Biotech CEO
3/2/2021
Neptune Wellness Solutions Inc. (NASDAQ: NEPT) (TSX: NEPT) President and CEO Michael Cammarata has been named one of the Top 25 Biotech CEOs of 2021 by The Healthcare Technology Report .
-
Adagio Therapeutics to Participate in Cowen 41st Annual Health Care Conference
2/22/2021
Adagio Therapeutics, Inc., a biotechnology company developing best-in-class antibodies to broadly neutralize coronaviruses, today announced that Tillman Gerngross, Ph.D., chief executive officer, and Jane Henderson, chief financial officer, will participate in one-on-one investor meetings during the Cowen 41st Annual Health Care Conference on Monday, March 1, 2021.
-
Adagio Therapeutics Announces Dosing of First Patient in Phase 1 Trial of ADG20, its Lead Monoclonal Antibody Candidate for the Treatment and Prevention of COVID-19
2/16/2021
-ADG20 is uniquely engineered to maximize potency, duration of effect, and ease of use in the community setting, and has shown outstanding manufacturability to meet global demand-
-
Adimab Provides Year-End Update on 2020 Partnership Activities
2/11/2021
Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, announced that in 2020 it entered into agreements with 11 new companies.
-
Adimab Provides 2020 Update on Clinical Pipeline
2/9/2021
Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that 11 new partner programs entered clinical development in 2020.
-
Adagio Therapeutics Publishes Preclinical Data in Science Demonstrating Best-in-Class Breadth and Potency Against SARS-CoV-2, Including Known Circulating Resistance Variants, and a Range of Pre-Emergent Coronaviruses
1/25/2021
Adagio Therapeutics, Inc., a biotechnology company developing best-in-class antibodies to broadly neutralize coronaviruses, today published in vitro and in vivo data in Science on its lead antibody candidate, ADG2, which demonstrated similar or higher potency against SARS-CoV-2 compared to other monoclonal antibodies (mAbs) in clinical development and strong binding to all known SARS-CoV-2 variants.
-
Adagio Therapeutics COVID-19 Antibody Demonstrates Best-in-Class Breadth and Potency Against a Range of Coronaviruses that Pose Human Threat
11/18/2020
Adagio Therapeutics, Inc., today pre-published in vitro and in vivo data demonstrating its lead antibody candidate, ADG2, shows similar or higher potency against SARS-CoV-2 compared to monoclonal antibodies (mAbs) in clinical development, while also uniquely offering broad neutralization against a range of sarbecoviruses that pose a threat to humans.
-
Adagio Therapeutics Raises $80M Series B Round to Further Advance Best-In-Class Antibodies for Coronavirus Treatment and Prevention
11/10/2020
Lead antibody - ADG20 - expected to advance to clinical studies in early 2021, offers potential best-in-class treatment and durable protection against SARS-CoV-2 and future coronaviruses
-
Adagio Therapeutics Strengthens Management Team with Appointments of Eric Kimble as Chief Commercial Officer and Ed Campanaro as SVP of Clinical Operations
9/9/2020
Adagio Therapeutics, Inc., a company focused on the development of best-in-class antibodies to provide broad protection against SARS-CoV-2, SARS-CoV-1 and additional circulating bat coronaviruses, announced it has strengthened its management team with the addition of Eric Kimble as Chief Commercial Officer and Ed Campanaro as Senior Vice President of Clinical Operations.
-
Adagio Therapeutics Announces Appointment of Howard Mayer, M.D., to its Board of Directors
8/24/2020
Adagio Therapeutics, Inc. announced that Howard Mayer, M.D., Executive Vice President and Head of Research and Development at Ipsen Pharmaceuticals, has joined its board of directors.
-
Adagio Therapeutics Launches With $50M Series A Financing to Advance the Development of Best-in-Class, Broadly Neutralizing Antibodies for Coronavirus Treatment and Prophylaxis
7/16/2020
Adagio Therapeutics Launches With $50M Series A Financing to Advance the Development of Best-in-Class, Broadly Neutralizing Antibodies for Coronavirus Treatment and Prophylaxis -Financing led by Polaris Partners and Mithril Capital, and includes investments by Fidelity funds, OrbiMed, M28 Capital, GV, and others- -Antibodies engineered to offer best-in-class, long-term protection against SARS-CoV-2 with utility against future coronaviruses-
-
Adimab Extenadimds Platform Partnership with Novo Nordisk
1/14/2020
This agreement extends an ongoing partnership between the two companies that began in 2013.
-
Adimab Provides 2019 Update on Clinical Pipeline
1/13/2020
Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, announced that 11 new partner programs entered clinical development in 2019.
-
Adimab Provides Year-End Update on 2019 Partnership Activities
1/10/2020
Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that in 2019 it entered into agreements with nine new companies.
-
Alector Announces the Addition of Kristine Yaffe, M.D., to the Board of Directors
8/12/2019
Alector, Inc. announced the addition of Kristine Yaffe, M.D., to the Company’s board of directors.
-
Adimab Announces Antibody Discovery Platform Transfer with Takeda
5/8/2019
Sixth pharma partner to internalize the Adimab platform
-
Adimab Expands Research Agreement with Regeneron
5/8/2019
Adimab, LLC, the leading provider of antibody discovery and optimization technology, announced the expansion of an earlier multi-target research agreement with Regeneron Pharmaceuticals.
-
Adimab Provides 2018 Update on Clinical Pipeline
1/9/2019
- 12 New Partner Programs Entered the Clinic in 2018 - - 21 Clinical Trials Initiated to Date -